WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F). - Stahl, M.; Roehmel, J.; Eichinger, M.; Doellinger, F.; Naehrlich, L.; Kopp, M.V.; Dittrich, A.-M.; Lee, C.; Sommerburg, O.; Tian, S.; Xu, T.; Wu, P.; et al. (Journal of Cystic Fibrosis, 2021)